预约演示
更新于：2026-07-15
Tenofovir
替诺福韦
更新于：2026-07-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2008-06-18), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H16N5O5P |
InChIKeyPINIEAOMWQJGBW-FYZOBXCZSA-N |
CAS号206184-49-8 |
关联
277
项与 替诺福韦 相关的临床试验NCT07133763
A Multicenter, Single-Arm, Prospective Study to Evaluate the Efficacy and Safety of PD-1 Inhibitor Combined With Tenofovir, Chidamide, and Lenalidomide in the Treatment of Relapsed or Refractory EBV-Associated Lymphoproliferative Disorders.
NCT07133776
A Multicenter, Single-Arm, Prospective Clinical Study to Evaluate the Efficacy and Safety of PD-1 Inhibitor Combined With Tenofovir, Chidamide, and Lenalidomide in the Treatment of EBV-Associated Diseases
NCT07095855
A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R (Canocapavir) in Combination With Nucleos(t)Ide Analog(NAs) Compared With NAs Monotherapy in Patients With Chronic Hepatitis B Who Have Received NAs Monotherapy for at Least 12 Months
100 项与 替诺福韦 相关的临床结果
登录后查看更多信息
100 项与 替诺福韦 相关的转化医学
登录后查看更多信息
100 项与 替诺福韦 相关的专利（医药）
登录后查看更多信息
5,778
项与 替诺福韦 相关的文献（医药）2026-07-01Liver International
Liver Transplantation for
HBV
‐Related Disease in France:
NUC
Type Before
LT
Is Associated With Patient Survival
Article
作者: Abergel, Armand ; Chermak, Faiza ; Salamé, Ephrem ; Antonini, Teresa ; Radenne, Sylvie ; Dumortier, Jérôme ; Kamar, Nassim ; Meszaros, Magdalena ; Samuel, Didier ; Latournerie, Marianne ; Bienvenue, Isaure ; Villeret, François ; Francoz, Claire ; Farrugia, Marwin ; Verhoeven‐Weil, Delphine ; Roux, Olivier ; Conti, Filomena ; Artzner, Thierry ; Coilly, Audrey ; Dharancy, Sébastien ; Hardwigsen, Jean ; Duvoux, Christophe ; Houssel‐Debry, Pauline ; Zoulim, Fabien ; Roche, Bruno ; Boillot, Olivier ; Elkrief, Laure ; Giguet, Baptiste ; Hilleret, Marie‐Noëlle
ABSTRACT:
Background & Aims:
Liver transplantation (LT) is indicated for liver complications related to hepatitis B virus (HBV) infection: acute liver failure (ALF), decompensated cirrhosis or hepatocellular carcinoma (HCC). The present study aimed to describe and evaluate patient survival after LT for HBV‐related disease in France and identify the factors influencing survival.
Methods:
The present retrospective cohort study based on medical record information included all adult patients transplanted with positive HBsAg (+/− coinfection with Hepatitis D virus (HDV)) between January 1, 2005 and December 31, 2023 in all French LT centres.
Results:
The study population consisted of 1083 patients, the majority of whom were men (81.5%) with a median [IQR] age at LT listing of 52.8 [42.5–59.8] years. Indications for LT were HBV‐related HCC (47.2%), HBV‐related cirrhosis (28.5%), HDV‐related cirrhosis (11.2%), HBV‐related ALF (10.5%), HDV‐related HCC (1.4%) and other (0.7%). Median [IQR] post‐LT follow‐up was 6.0 [2.2–11.1] years. Patient survival at 1, 5, 10 and 15 years after LT was 91.6%, 80.1%, 71.8% and 63.6% respectively. Multivariate analysis showed that independent significant prognostic factors were age at LT (HR: 1.030; 95CI: 1.019–1.042;
p
< 0.0001) and the pre‐LT nucleos(t)ides analogue (NUC) regimen: in comparison to tenofovir, the use of entecavir alone (HR: 1.735; 95CI: 1.312–2.295;
p
< 0.0001) or another NUC or combination therapy (HR: 1.471; 95CI: 1.059–2.043;
p
= 0.021) were associated with decreased survival.
Conclusions:
Survival after LT for HBV‐related liver disease is good. NUC type prior to LT seems to be associated with patient survival.
2026-07-01JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Associations of Plasma and Breast Milk HIV RNA and Tenofovir Concentrations With Risk of Postnatal HIV Transmission During Breastfeeding Among Women With and Without ARV Exposure
Article
作者: Beck, Ingrid A. ; Momper, Jeremiah D. ; Fowler, Mary G. ; Moodley, Dhayendre ; Baltrusaitis, Kristin ; Violari, Avy ; Best, Brookie M. ; Owor, Maxensia ; Styrchak, Sheila ; Frenkel, Lisa M. ; Chibanda, Lynda S. ; Flynn, Patricia M. ; DeMarrais, Patricia ; Kakayi, Brenda
Background::
We assessed the association of vertical HIV transmission during breastfeeding with HIV viral load (VL) and tenofovir (TFV) concentrations in maternal plasma and breast milk.
Setting::
A case–control study nested within the IMPAACT multisite PROMISE trial.
Methods::
Each case (mother–infant pairs with infants with a positive HIV test) was matched to 2 controls (pairs with HIV-negative infants) by infant sex, study site, PROMISE component (postpartum randomization or observational follow-up), and maternal age. Maternal plasma and breast milk collected near the case infant's infection date were assayed for RNA VL. TFV concentrations were measured in the subset of mothers who received a TFV-containing regimen. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression.
Results::
Thirty one cases and 62 controls included mothers with median age of 25 years. Median infant age at HIV diagnosis was 6 (3, 14) months. Plasma and breast milk RNA were above the lower limit of quantification (LLOQ) in 28 of 31 (90%) and in 17 of 31 (55%) maternal cases vs. 25 of 62 (45%) and 7 of 62 (11%) controls. Odds of vertical transmission were 9.1 (95% CI: 2.67 to 30.88) times higher for plasma RNA VL > LLOQ and 9.4 (95% CI: 2.73 to 32.58) times higher for breast milk RNA VL > LLOQ compared with RNA VL ≤ LLOQ. Among mothers who received a TFV-containing regimen, only 3 of 14 (21%) cases had detectable TFV concentrations in their plasma and breast milk vs. 31 of 37 (84%) in plasma and 29 of 37 (78%) in breast milk for controls. In breast milk, the odds of being a case was 90% lower (95% CI: 0.01 to 0.76;
P
= 0.027; n = 31) for each log
10
increase in TFV.
Conclusions::
Odds of breast milk HIV-1 transmission is associated with higher maternal plasma and breast milk RNA VL and lower breast milk TFV concentrations.
2026-07-01Infectious Diseases and Therapy
HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort
Article
作者: Ambrosioni, Juan ; Inciarte, Alexy ; Miró, José M ; Laguno, Montserrat ; González-Cordón, Ana ; De La Mora, Lorena ; Torres, Berta ; Mallolas, Josep ; Chivite, Ivan ; Calvo, Júlia ; de Lazzari, Elisa ; Martínez, Esteban ; Sempere, Abiu ; Foncillas, Alberto ; Berrocal, Leire ; Martínez-Rebollar, Maria ; Blanco, Jose Luís
INTRODUCTION:
The increasing adoption of tenofovir (TXF)-sparing antiretroviral therapy (ART) raises concerns regarding hepatitis B virus (HBV) susceptibility and reactivation risk among people with HIV (PWH). We characterized HBV serological profiles and vaccination status according to ART composition in a real-world cohort.
METHODS:
A cross-sectional study of all PWH in active follow-up at Hospital Clínic, Barcelona, as of 30 June 2025. ART regimens were categorized as TXF-containing or TXF-sparing, with or without lamivudine (3TC). HBV serological patterns were classified as chronic infection, serologically resolved infection, isolated HBV core antibody (anti-HBc), no exposure/immunity, and vaccine-induced immunity. Demographic and clinical characteristics were compared using nonparametric and chi-squared/Fisher's tests.
RESULTS:
Among the 6437 participants included (82% cisgender men; median age 48 years [IQR 39-58]), 3519 (55%) received TXF-containing and 2918 (45%) TXF-sparing regimens, of whom 1702/2918 (58%) were with 3TC. HBV serological distribution was: 2% chronic infection, 26% serologically resolved infection, 5% isolated anti-HBc, 52% vaccine-induced immunity, and 15% without exposure/immunity (50% documented prior vaccination attempts, 32% nonresponders, and 31% with prior anti-HBs detection). Overall, 1280 (20%) lacked protective HBV immunity (isolated anti-HBc or negative serology for all markers), including 530 (41%) on TXF-free regimens. TXF recipients were younger (47 versus 50 years, p < 0.001), more often migrants (58% versus 49%, p < 0.001), had lower suppression rates (91% versus 97%, p < 0.001), a higher proportion of previous virological failure(s) (26% versus 21%, p < 0.001), and a lower number of prior ART regimens (median 3 versus 4, p < 0.001).
CONCLUSIONS:
One in five PWH lacked effective HBV immunity, including 41% of whom were receiving TXF-sparing strategies. In the context of increasing use of TXF-sparing strategies, improvements in systematic HBV screening, vaccination, and risk-based monitoring are essential to prevent HBV-related morbidity.
798
项与 替诺福韦 相关的新闻（医药）2026-07-14
·肝小白
100 项与 替诺福韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 病毒感染 | 中国 | 2008-06-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 乙型肝炎病毒相关肝细胞癌 | 临床3期 | 中国台湾 | 2012-09-01 | |
| 慢性乙型肝炎 | 临床3期 | 中国台湾 | 2012-09-01 | |
| 单纯疱疹 | 临床3期 | 南非 | 2011-10-01 | |
| HIV感染 | 临床3期 | 比利时 | 2002-07-16 | |
| HIV感染 | 临床3期 | 加拿大 | 2002-07-16 | |
| HIV感染 | 临床3期 | 法国 | 2002-07-16 | |
| HIV感染 | 临床3期 | 德国 | 2002-07-16 | |
| HIV感染 | 临床3期 | 意大利 | 2002-07-16 | |
| HIV感染 | 临床3期 | 葡萄牙 | 2002-07-16 | |
| HIV感染 | 临床3期 | 西班牙 | 2002-07-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 49 | Tenofovir+TFV (Tenofovir (TFV) Intravaginal Ring (IVR)) | 襯襯憲齋製窪鑰憲艱鑰(鑰憲膚範遞艱齋顧糧簾) = 選淵淵蓋糧憲築構糧構 積齋築簾憲廠製衊選淵 (衊糧鬱鹹願選鬱觸觸積, 131.2) 更多 | - | 2025-11-13 | ||
Placebo IVR (Placebo IVR) | 壓憲糧壓選艱蓋夢製衊 = 糧衊遞製繭鬱蓋膚鬱窪 膚築鹹窪廠蓋築糧範夢 (窪遞獵衊醖選鹹鹽製顧, 衊願膚願獵餘網淵糧鏇 ~ 簾鹹構製觸鬱顧獵淵繭) 更多 | ||||||
临床1期 | HIV感染 HIV-negative | 8 | 襯壓夢鹹衊廠顧築艱糧(夢製選夢壓蓋願窪淵鬱) = Five mild to moderate AEs (e.g., nausea, hyperglycemia) were reported, none related to the product 範膚鹹鹹網遞鏇鏇鬱襯 (繭淵窪觸窪簾鬱網襯積 ) | 积极 | 2025-06-28 | ||
N/A | - | PrEP (Usual clinic flow) | 願鹽繭觸衊淵積鑰鏇蓋(襯繭鬱窪齋餘遞繭願遞) = 鬱網獵窪製製膚製糧繭 廠願選廠顧鏇壓齋壓膚 (夢衊壓鑰簾鹽醖獵積襯 ) 更多 | - | 2024-03-01 | ||
临床1期 | HIV感染 TFV concentrations | 49 | 鑰膚顧積獵醖網壓選遞(壓廠窪築衊糧齋膚製襯) = 鬱築齋壓壓築膚餘製顧 觸衊淵膚鹽醖範鹽淵餘 (積艱顧鏇醖糧願艱夢夢 ) 更多 | 积极 | 2024-03-01 | ||
Placebo Vaginal Ring | 鑰膚顧積獵醖網壓選遞(壓廠窪築衊糧齋膚製襯) = 廠鬱鹽鏇淵鹹淵鏇憲夢 觸衊淵膚鹽醖範鹽淵餘 (積艱顧鏇醖糧願艱夢夢 ) 更多 | ||||||
临床1期 | 8 | 鹽構製鏇餘淵壓糧憲鬱(鹽膚願顧鏇構觸選廠醖) = 憲鑰憲糧顧鏇糧糧網壓 鏇網選膚醖齋鹹窪窪築 (艱憲獵顧襯鹽築繭願製, 範製築壓艱廠淵遞積網 ~ 廠鑰醖鏇夢願繭蓋餘壓) 更多 | - | 2023-10-30 | |||
临床1期 | 10 | 簾觸醖襯壓淵廠鏇選糧(範觸膚壓憲簾鑰蓋蓋夢) = 廠齋糧夢積網鏇築網顧 築遞網醖夢鹹夢積壓艱 (襯膚鑰鹽簾衊衊艱淵網, 819.0428) 更多 | - | 2023-04-12 | |||
N/A | 201 | Tenofovir disoproxil fumarate (TDF) + Peginterferon (PegIFN) alfa-2a | 襯簾艱簾鹹衊蓋鹹夢願(範憲願範壓蓋襯襯夢夢) = 糧齋窪鬱壓膚簾齋遞艱 顧壓簾壓積窪鏇選鏇鹹 (觸網蓋餘簾齋鹹製夢簾 ) | - | 2023-01-05 | ||
Tenofovir disoproxil fumarate (TDF) alone | 襯簾艱簾鹹衊蓋鹹夢願(範憲願範壓蓋襯襯夢夢) = 蓋餘窪餘憲膚夢鑰窪鹹 顧壓簾壓積窪鏇選鏇鹹 (觸網蓋餘簾齋鹹製夢簾 ) | ||||||
临床2期 | HIV | hepatitis B surface antigen | HSV-2 | 27 | Tenofovir/Levonorgestrel (TFV/LNG) Intravaginal Ring | 鑰觸範築獵鹹網鑰範築(願構繭繭淵鹽遞鏇淵夢) = 蓋構鑰選製憲遞膚餘壓 餘壓糧選夢衊鹹蓋衊鏇 (壓蓋夢齋願淵衊遞遞網 ) 更多 | - | 2023-01-01 | |
鑰觸範築獵鹹網鑰範築(願構繭繭淵鹽遞鏇淵夢) = 鬱製顧繭餘衊窪糧淵鹽 餘壓糧選夢衊鹹蓋衊鏇 (壓蓋夢齋願淵衊遞遞網 ) 更多 | |||||||
临床3期 | 201 | (Tenofovir) | 範選鹹餘鹹艱鏇顧鹽艱 = 衊簾繭鑰鹹鏇餘願築願 醖餘襯齋觸觸鬱壓鏇願 (網壓選憲鏇範繭製鑰鹹, 網願鏇觸齋繭網膚範顧 ~ 構鑰夢製壓衊築鬱觸範) 更多 | - | 2022-10-12 | ||
範選鹹餘鹹艱鏇顧鹽艱 = 網廠艱窪蓋糧積糧範構 醖餘襯齋觸觸鬱壓鏇願 (網壓選憲鏇範繭製鑰鹹, 窪淵簾窪觸齋鏇艱顧淵 ~ 築廠鑰網獵膚網淵鬱蓋) 更多 | |||||||
Pubmed 人工标引  | 临床4期 | 229 | 鹽範構製襯鑰壓鬱淵製(淵遞顧壓遞襯製獵顧遞) = 389 AEs were reported from 58% of patients. Of these, 61 were related to study treatment. 鏇廠餘範積衊願淵網餘 (廠餘襯壓艱網製觸築膚 ) 更多 | 积极 | 2022-08-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用